PREGNANCY AND BREASTFEEDING SAFETY:
- Lovenox does not cross the placenta and shows no evidence of effects on the fetus. It often is used during pregnancy as an alternative to oral anticoagulants such as warfarin (Coumadin), which cannot be safely used during pregnancy.
- Lovenox multiple-dose vials contain benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "gasping syndrome" in premature neonates. Lovenox vials preserved with benzyl alcohol should be used with caution in pregnant women and only if clearly needed because benzyl alcohol may cross the placenta.
- It is not known if Lovenox is excreted in breast milk. Since most medicines are excreted in breast milk, it is recommended that women receiving Lovenox should not breastfeed.
- Lovenox is available in pre-filled syringes containing 30, 40, 60, 80, 100, 120, and 150 mg.
- Multiple dose vial: 300 mg
STORAGE: All Lovenox products should be stored at room temperature, between 15 and 30 C (59 and 86 F).
How does Lovenox (enoxaparin) work?
- Enoxaparin is a low molecular weight heparin (LMWH) that is used to prevent blood clots. It is produced by chemically breaking heparin into smaller-sized molecules. Unlike heparin, the effect of enoxaparin does not need to be monitored with blood tests. Like heparin, enoxaparin prevents blood clots from forming by blocking the action of two of the 12 clot-promoting proteins in blood (factors X and II) whose action is necessary for blood to clot. Enoxaparin is used to treat or prevent blood clots and their complications (deep vein thrombosis or DVT and pulmonary embolism or PE). Deep vein thrombosis is the formation of blood clots in veins deep in a muscle, most often in the legs deep vein thrombosis may lead to pulmonary embolism, a condition in which a piece of the clot (the embolus) breaks loose and travels through the veins to the lung. In the lung the clot blocks an artery and prevents the part of the lung that is supplied by the artery from working normally. If the artery that is blocked is a large artery, the embolus can cause sudden death. Thrombosis and embolism are responsible for 300,000 to 600,000 hospitalizations each year, and pulmonary embolism causes as many as 200,000 deaths each year in the U.S. Patients undergoing hip replacement and other major surgery are at increased risk of deep vein thrombosis and pulmonary embolism.
- he FDA approved enoxaparin in 1993.
Reference: FDA Prescribing Information
Quick GuideDVT in Pictures: Symptoms of Deep Vein Thrombosis, Beyond Leg Pain and More
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.